Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

The anti-HER2 monoclonal antibody trastuzumab is a key drug for the treatment of HER2-positive gastric cancer (GC); however, its activity is often limited by the onset of resistance and mechanisms of resistance are still poorly understood. Several targeted agents showed synergistic activity by conco...

Full description

Bibliographic Details
Main Authors: Maria Maddalena Laterza, Vincenza Ciaramella, Bianca Arianna Facchini, Elisena Franzese, Carmela Liguori, Stefano De Falco, Paola Coppola, Luca Pompella, Giuseppe Tirino, Massimiliano Berretta, Liliana Montella, Gaetano Facchini, Fortunato Ciardiello, Ferdinando de Vita
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
PI3K
AKT
HER3
ipatasertib
duligotuzumab
trastuzumab
Online Access:https://www.mdpi.com/2072-6694/13/10/2339

Internet

https://www.mdpi.com/2072-6694/13/10/2339

Similar Items